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mography ranged from (2015US)$7,221-$39,251/QALY compared to no screening. 
Also for high-risk women, combined MRI and mammography were associated 
with ICERs from (2015US)$19,288/QALY to dominant compared to mammogra-
phy alone. These results include women of any age and mammography of any 
type. ConClusions: Results suggest that annual mammography is mostly 
cost-effective when compared to no screening. According to a $100,000/QALY 
threshold, most of analyzed studies suggest that combined screening is cost-
effective in high-risk women compared to mammography alone, despite a wide 
cost-effectiveness ratios range. Notwithstanding the high level of heterogeneity 
among selected studies, this review provides a comprehensive overview of the 
cost-effectiveness of BCS and could serve in the realization of future economic 
evaluations.
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objeCtives: Glioblastoma is a most aggressive primary brain tumor. Few eco-
nomic evaluations have been performed to evaluate treatments in glioblastoma. 
The objective of this literature review was to identify the characteristics of eco-
nomic evaluations in glioblastoma and the methods used to assess their economic 
impact. Methods: A literature search was performed using MEDLINE and EMBASE 
electronic databases from January 2004 until February 2014 to identify economic 
evaluations of glioblastoma. Titles were initially screened for relevance. Then, 
abstracts of potentially relevant studies were reviewed. Finally, full-text articles were 
obtained for studies deemed relevant according to the abstract and were analyzed 
in details and relevant characteristics were extracted. Results: A total of 1,666 
potentially relevant studies were identified. After screening titles and abstracts, 105 
full-text articles were assessed according to the eligibility criteria and 14 studies 
were included. Cost-effectiveness and cost-utility analyzes were performed in 86% 
of studies. Thirty six percent of the economic evaluations used a Markov model 
and fourteen percent used a decision tree. The time horizon varied from 1 year to 
lifetime, with 57% of studies with a time horizon of more than 5 years. A large major-
ity of the economic evaluations adopted the perspective of the healthcare system 
(n= 12) and two studies reported societal perspective. The largest proportion of the 
studies compared temozolomide to several chemotherapy used in glioblastoma 
(57%), followed by bevacizumab (7%), carmustine wafer (7%). Among studies that 
reported a cost per QALY or a cost per LYG (9 studies). Among these, 29% have an 
ICER of CAD$50,000 or less, while 43% have an ICER of CAD$100,000/(QALY, LYG) 
or less. ConClusions: Despite the high level of heterogeneity among selected 
studies, this review provides a comprehensive overview of the cost-effectiveness 
of several treatments in glioblastoma and could serve in the realization of future 
economic evaluations.
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objeCtives: The objective was to evaluate the cost-effectiveness of an oral fixed 
combination netupitant and palonosetron (NEPA) compared with aprepitant and 
palonosetron (APPA) or palonosetron (PA) alone, to prevent chemotherapy-induced 
nausea and vomiting (CINV) in patients undergoing treatment with highly or mod-
erately emetogenic chemotherapy (HEC or MEC) in the UK. Methods: A systematic 
literature review and meta-analysis were undertaken to compare NEPA with currently 
recommended anti-emetics. Relative effectiveness was estimated over the acute (day 
1) and overall treatment (day 1-5) phases, taking complete response (CR, no emesis no 
rescue medication) and complete protection (CP, CR plus no more than mild nausea) 
as primary efficacy outcomes. A three health-state Markov cohort model, including 
CP, CR and incomplete response (no CR) for HEC and MEC, was constructed. A five 
day time horizon and UK NHS perspective were adopted. Transition probabilities 
were obtained by combining the response rates of CP and CR from NEPA trials and 
odds ratios from the meta-analysis. Utilities of 0.90, 0.70 and 0.24 were defined for CP, 
CR and incomplete response, respectively. Costs included medications and manage-
ment of CINV-related events and were obtained from the British National Formulary 
and NHS Reference Costs. The expected budgetary impact of NEPA was also evalu-
ated. Results: In HEC patients, the NEPA strategy was more effective than APPA 
(quality-adjusted life days [QALDs] of 4.263 versus 4.053; incremental emesis- and 
CINV-free days of +0.354 and +0.237 respectively) and was less costly (£66 versus £124), 
resulting in NEPA being the dominant strategy. In MEC patients, NEPA was also domi-
nant, cumulating in an estimated 0.182 extra QALDs at an incremental cost of -£7.35 
compared with PA. Introducing NEPA is estimated to provide net 5-year cumulative 
cost savings of £13,981,628. ConClusions: The results suggest NEPA is cost-effective 
for preventing CINV associated with HEC and MEC in the UK.
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four studies included the word “cost”, three “economics” and none “budget” in head-
ing or abstract. None of the publications were thorough of cost analysis (cost-effec-
tiveness, cost-utility, cost-minimizing or cost-of-illness analysis). Six HTAs and eight 
national guidelines were identified. The cost per quality adjusted life year (QALY) 
was indicated € 80.000-€ 94,000. HTAs concluded reimbursement being not recom-
mendable or no ultimate statement could be made. One pointed towards a limited 
use with caution. ConClusions: Guidelines were based on data from randomized 
clinical trials (RCTs). Health economics was not considered when guidelines were 
made. Most HTAs concluded this therapy not cost-effective or there was insufficient 
data for final conclusions. Licensing and reimbursement processes should be run 
simultaneously.
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objeCtives: The main objective behind conducting this study was to evaluate the 
cost-effectiveness of fluvestratnt 500 mg against, exemestene in the treatment of 
metastatic breast cancer, for the Egyptian patients, from the national fund perspec-
tive over a time horizon of 3 years. Methods: Markov chain model was applied 
with three health states. Utility data were incorporated. Costs were that of the 
fund list. Results presented in of QALYs. One-dimensional sensitivity analyses were 
employed. Results: During the three-year time horizon the total cumulative QALY 
gained for fluvestrant 500 mg was 1.58 QALY The total cumulative QALY gained for 
exemestene was a 0.43 QALY. ConClusions: The introduction of fluvestrant 500 
mg to the national fund - system was found to be cost saving based strictly from its 
perspective the model addresses both the health and economic implications of both 
drugs. The result of the study suggest that fluvestrant 500 and helping for taking the 
decision for resource allocation towards the cost saving treatment .
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objeCtives: To evaluate the cost-effectiveness of adding bevacizumab to single-
agent chemotherapy for platinum-resistant recurrent ovarian cancer. Methods: 
A decision-tree model was constructed to evaluate the cost-effectiveness of adding 
bevacizumab to standard treatment with single-agent chemotherapy (BEV + CT) as 
compared to treatment with single-agent chemotherapy alone. Transition probabili-
ties were based on findings from AURELIA, an international randomized phase III 
clinical trial and the first to evaluate the survival benefits of adding bevacizumab 
to chemotherapy for women with platinum-resistant disease. Quality-adjusted 
life-years (QALYs), progression-free survival (PFS), and costs were modeled over a 
horizon of fifteen months. Assuming a U.S. public payer perspective, incremental 
cost-effectiveness ratios (ICERs) were evaluated as the incremental cost per QALY 
gained and the incremental cost per progression-free life-year saved. To evaluate 
the robustness of our results, we performed deterministic and probabilistic sensi-
tivity analyses. Results: The ICERs associated with BEV + CT were $285,624 per 
QALY gained and $151,059 per progression-free life-year saved. Varying transition 
probabilities, costs, and utilities across the expected distribution of each parameter 
resulted in 7.2% of ICER estimates falling below the commonly accepted willingness 
to pay (WTP) threshold of $50,000/QALY gained; at a WTP threshold of $100,000/QALY 
gained, 22% of ICER estimates were cost-effective. One-way deterministic sensitivity 
analysis suggests that BEV + CT would become cost-effective at a WTP threshold of 
$50,000/QALY gained if the cost of treatment was reduced by 65%. ConClusions: 
Despite gains in QALYS and PFS, the addition of bevacizumab to single-agent chemo-
therapy for the treatment of platinum-resistant recurrent ovarian cancer would not 
be considered cost effective at a willingness to pay threshold of $50,000/QALY gained 
or $100,000/QALY gained. On a per-patient basis, individual expected benefits, risks, 
and costs associated with treatment should be taken into consideration when pre-
scribing bevacizumab.
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objeCtives: The objective of this literature review was to explore the existing 
evidences regarding cost-effectiveness of breast cancer screening (BCS) tests in 
average-risk women and in high-risk women. Methods: A literature review was 
performed using the PICO method: Population consisted of women at average risk 
and at high risk for breast cancer; Intervention and Comparators were BCS tests, 
and Outcomes were incremental cost-effectiveness ratios (ICERs). The literature 
search was performed with the NHS EED filters using the electronic databases 
(MEDLINE, EMBASE and PubMed) from January 2005 until May 2015. Results: The 
literature review allowed retrieving 1,699 studies of which 39 fulfilled the eligibility 
criteria. Fourteen studies were cost-effectiveness analyses, twenty-one were cost-
utility analyses and four were both. Eighteen studies used a Markov model while 
seven studies used a decision tree. Time horizon varied from 5 years to lifetime. 
Main interventions compared were no screening, biennial mammography, annual 
mammography and annual mammography combined to MRI. For average-risk 
women, ICERs for biennial mammography varied between (2015US)$4,715-$21,747/
LYG and between (2015US)$7,548-$107,590/QALY compared to no screening, 
while ICERs for annual mammography ranged from (2015US)$24,124-$40,266/
LYG and (2015US)$69,217/QALY. For high-risk women, ICERs for annual mam-
